Teen drinking is a serious concern: Not a surprise finding

Article

In all campaigns to combat substance abuse by adolescents, the spotlight is usually on illicit substances—marijuana, heroin, crack, Ecstasy, or whatever else is the teenage drug-du-jour.

Recent Videos
Diet, mental health, and pediatric nutrition, with Colleen Sloan, PA-C, RDN
Victor Carrion, MD
Tina Tan, MD, comments on FDA expanded approval for MenQuadfi meningococcal disease vaccine
Tina Tan, MD, discusses impact of FDA's stricter COVID-19 vaccine policy for children
Jennifer Soung, MD reacts to FDA approval of roflumilast foam 0.3%
Supporting mental health in pediatric primary care with Victor Carrion, MD
Discussing social media and potential nutrition impacts with Colleen Sloan, PA-C, RDN
Jenna Marcovitz, MA explains how music therapy helps in pediatric care
Related Content
Weekly review: Clesrovimab for RSV approved, new dupilumab data, and more

Weekly review: Clesrovimab for RSV approved, new dupilumab data, and more

Joshua Fitch, Senior Editor
June 13th 2025
Article

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

Site Logo

Food Insecurity and the Dangers of Infant Formula Dilution

January 30th 2023
Podcast
Bavarian Nordic initiates trial of chikungunya vaccine in children aged 2-11 years | Image Credit: © ImageKing - © ImageKing - stock.adobe.com.

Bavarian Nordic initiates trial of chikungunya vaccine in children aged 2-11 years

Joshua Fitch, Senior Editor
June 13th 2025
Article

Currently, Vimkunya is FDA-approved for use among individuals aged 12 years and older.

Demystifying Infant Formula

Demystifying Infant Formula

October 11th 2022
Podcast
Michael Daines, MD, discusses pediatric acute-onset neuropsychiatric syndrome

Michael Daines, MD, discusses pediatric acute-onset neuropsychiatric syndrome

Michael O. Daines, MD
June 12th 2025
Article

Michael O. Daines, MD, outlines key diagnostic criteria and treatment challenges for pediatric acute-onset neuropsychiatric syndrome (PANS), emphasizing the need for multidisciplinary care and improved treatment access.

FDA expands glecaprevir/pibrentasvir indication for acute hepatitis C down to 3 years of age | Image credit: Contemporary Pediatrics

FDA expands glecaprevir/pibrentasvir indication for acute hepatitis C down to 3 years of age

Joshua Fitch, Senior Editor
June 12th 2025
Article

Glecaprevir/pibrentasvir was a "highly efficacious treatment for people with acute HCV," with 96.2% of patients analyzed having sustained virological response 12 weeks post-treatment.

© 2025 MJH Life Sciences

All rights reserved.